European expert opinion on the management of invasive candidiasis in adults.

Details

Serval ID
serval:BIB_E07440329754
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
European expert opinion on the management of invasive candidiasis in adults.
Journal
Clinical Microbiology and Infection
Author(s)
Kullberg B.J., Verweij P.E., Akova M., Arendrup M.C., Bille J., Calandra T., Cuenca-Estrella M., Herbrecht R., Jacobs F., Kalin M., Kibbler C.C., Lortholary O., Martino P., Meis J.F., Muñoz P., Odds F.C., De Pauw B.E., Rex J.H., Roilides E., Rogers T.R., Ruhnke M., Ullmann A.J., Uzun Ö., Vandewoude K., Vincent J.L., Donnelly J.P.
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Publication state
Published
Issued date
2011
Volume
17
Number
Suppl. 5
Pages
1-12
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad answering system. After the initial conference, the viewpoint document has been reviewed and edited to include new insights and developments since the initial meeting. For many situations, consensus on treatment could not be reached, and the responses indicate that treatment is likely to be modified on a patient-to-patient basis, depending on factors such as degree of illness, prior exposure to azole antifungals, and the presence of potentially antifungal drug-resistant Candida species.
Keywords
candida, candidaemia, consensus, guidelines, therapy, INTENSIVE-CARE-UNIT, LIPOSOMAL AMPHOTERICIN-B, CRITICALLY-ILL PATIENTS, EMPIRICAL ANTIFUNGAL THERAPY, PLACEBO-CONTROLLED TRIAL, NON-ALBICANS CANDIDEMIA, DOUBLE-BLIND TRIAL, SURGICAL-PATIENTS, PERSISTENT FEVER, ANTIMANNAN ANTIBODIES
Pubmed
Web of science
Open Access
Yes
Create date
29/09/2011 9:02
Last modification date
20/08/2019 16:04
Usage data